Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.78 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1097495 | 0.89 | TSHR (1.00) | TSHRMEN1KMT2AALDH1A1ACHE | |
| SCHEMBL539064 | 0.84 | ALDH1A1 (0.60) | TSHRMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL65293 | 0.84 | CYP19A1 (0.62) | TSHRMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL635130 | 0.84 | TSHR (0.90) | TSHRMEN1KMT2AALDH1A1ACHE | |
| Morpholine SCHEMBL28321649 | 0.82 | TSHR (0.53) | TSHRMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL7896134 | 0.79 | NPC1 (0.68) | TSHRMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL5538329 | 0.79 | CYP19A1 (0.62) | TSHRMAPTALDH1A1CYP3A4POLB | |
| Urea SCHEMBL3678424 | 0.76 | SMN1; SMN2 (0.63) | TSHRMAPTALDH1A1NPC1CYP3A4 | |
| SCHEMBL1718796 | 0.74 | ALDH1A1 (0.50) | TSHRMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL1863964 | 0.74 | ALDH1A1 (0.52) | TSHRMAPTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725554-A2 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2026-04-15 | — | — | EP | disclosed |
| US-RE50528-E1 | Compounds and compositions for modulating EGFR mutant kinase activities | YUHAN CORPORATION (KR) | 2025-08-12 | — | — | US | disclosed |
| US-20250179013-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-4563146-A1 | FLAVIVIRUS INHIBITORS | IRBM S.P.A. (IT) | 2025-06-04 | — | — | EP | disclosed |
| EP-4479380-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | Accent Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-3929190-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORP (KR) | 2024-12-25 | — | — | EP | disclosed |
| EP-4421069-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2024-08-28 | — | — | EP | disclosed |
| EP-4306535-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED USING SAME | AJINOMOTO CO., INC. (JP) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023158795-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| EP-0355326-B1 | Nonlinear optical material | SUMITOMO BAKELITE CO (JP) | 1993-10-27 | — | — | EP | disclosed |
| US-5254135-A | Applying indole dye, developing with oxidizing system | L'OREAL (FR) | 1993-10-19 | — | — | US | disclosed |
| EP-0564409-A1 | Pyrimidin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-10-06 | — | — | EP | disclosed |
| US-5110988-A | N-methoxymethyl-4-nitroaniline | SUMITOMO BAKELITE COMPANY LIMITED (JP) | 1992-05-05 | — | — | US | disclosed |
| EP-0355326-A2 | Nonlinear optical material | SUMITOMO BAKELITE COMPANY LIMITED (JP) | 1990-02-28 | — | — | EP | disclosed |
| EP-0081157-B1 | PROCESS FOR THE PREPARATION OF N-NITROARYL-NITROARYL CARBOXAMIDES | BAYER AG (DE) | 1985-01-02 | — | — | EP | disclosed |
| EP-0081157-A1 | Process for the preparation of N-nitroaryl-nitroaryl carboxamides | BAYER AG (DE) | 1983-06-15 | — | — | EP | disclosed |
| US-4304922-A | REDOX SYSTEMS COMPRISING A UREA, AN ALCOHOL, CARBON MONOXIDE, OXYGEN, A REDUCIBLE METAL SALT, AND A CATALYTIC GROUP 8 METAL SALT | BAYER AKTIENGESELLSCHAFT (DE) | 1981-12-08 | — | — | US | disclosed |
| EP-0016949-B1 | PROCESS FOR PREPARING URETHANES | BAYER AG (DE) | 1981-10-14 | — | — | EP | disclosed |
| EP-0016949-A1 | Process for preparing urethanes | BAYER AG (DE) | 1980-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179013-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX9, DHX29, DDX39B | TSHR 4733/4885MAPT 3830/4885MEN1 3047/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | TSHR 2696/4885MAPT 3976/4885MEN1 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.